UTHR
NASDAQ · Biotechnology
United Therapeutics Corp
$586.94
+4.48 (+0.77%)
Financial Highlights (FY 2026)
Revenue
2.87B
Net Income
1.20B
Gross Margin
87.9%
Profit Margin
41.9%
Rev Growth
+18.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 87.9% | 87.9% | 63.2% | 63.2% |
| Operating Margin | 46.9% | 42.2% | 18.6% | 18.9% |
| Profit Margin | 41.9% | 39.8% | 14.9% | 13.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.87B | 2.43B | 2.73B | 2.22B |
| Gross Profit | 2.52B | 2.14B | 1.73B | 1.40B |
| Operating Income | 1.35B | 1.03B | 507.41M | 420.44M |
| Net Income | 1.20B | 917.69M | 406.29M | 307.07M |
| Gross Margin | 87.9% | 87.9% | 63.2% | 63.2% |
| Operating Margin | 46.9% | 42.2% | 18.6% | 18.9% |
| Profit Margin | 41.9% | 39.8% | 14.9% | 13.8% |
| Rev Growth | +18.0% | +18.0% | +4.0% | +2.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 6.76B | 6.24B |
| Total Equity | — | — | 12.89B | 12.35B |
| D/E Ratio | — | — | 0.52 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 1.42B | 1.15B | 733.08M | 605.29M |
| Free Cash Flow | — | — | 513.48M | 304.80M |